Blog
RSS FeedPosted by Michael Wonder on 05 Dec 2023
Government sends mixed message to global life science investors
5 December 2023 - The Government has published new terms for the Statutory Scheme for branded medicines, maintaining sales rebates ...
Posted by Michael Wonder on 01 Dec 2023
Pembrolizumab with trastuzumab and chemotherapy for the first-line treatment of patients with advanced HER2 positive gastric or gastro-oesophageal junction cancer
1 December 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Nov 2023
Cabozantinib maleate with nivolumab for patients with untreated advanced renal cell carcinoma
30 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Nov 2023
Idecabtagene vicleucel for the treatment of patients with relapsed and refractory multiple myeloma after 3 or more treatments
30 November 2023 - NICE is unable to make a recommendation on the use of idecabtagene vicleucel (Abecma) for the treatment ...
Posted by Michael Wonder on 29 Nov 2023
Belzutifan for the treatment of patients with a tumour associated with von Hippel-Lindau disease
29 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Nov 2023
Tisagenlecleucel for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
29 November 2023 - NICE is unable to make a recommendation on the use of tisagenlecleucel (Kymriah) for the treatment of ...
Posted by Michael Wonder on 29 Nov 2023
Foslevodopa with foscarbidopa for the treatment of patients with advanced Parkinson’s with motor symptoms
29 November 2023 - NICE has published final evidence-based recommendations on the use of foslevodopa with foscarbidopa (Produodopa) for the ...
Posted by Michael Wonder on 27 Nov 2023
Lifeline for Wolman disease kids as NICE backs Alexion drug
27 November 2023 - Infants with a rare and fatal congenital disorder called Wolman disease in England and Wales will ...
Posted by Michael Wonder on 24 Nov 2023
Ritlecitinib tosylate for the treatment of people with alopecia areata
24 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Nov 2023
Cedazuridine with decitabine for patients with untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
23 November 2023 - NICE is unable to make a recommendation on the use of cedazuridine with decitabine (Inaqovi) for the ...
Posted by Michael Wonder on 22 Nov 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia (final guidance)
22 November 2023 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 20 Nov 2023
Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment
20 November 2023 - Pro-innovation and pro-competition agreement will introduce a new mechanism to support lower industry payment rates for more ...
Posted by Michael Wonder on 20 Nov 2023
NICE gets ready to assess new dementia treatments
20 November 2023 - NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the ...
Posted by Michael Wonder on 15 Nov 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with metastatic PSMA positive hormone-relapsed prostate cancer after two or more treatments
15 November 2023 - NICE has published final evidence-based recommendations on the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) ...
Posted by Michael Wonder on 07 Nov 2023
NICE launches refreshed support service for life sciences industry
6 November 2023 - NICE has today launched its refreshed support service for the life sciences sector, NICE Advice. ...